Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Woman gives birth on roadside after hospital allegedly sent her home: Family - 2Flat Earth, spirits and conspiracy theories – experience can shape even extraordinary beliefs
- 3Scaling New Levels: Rock Climbing Spots On the planet
- 4Avoid Slam: Clearing the Street for the Eventual fate of Standard Size Trucks
- 5How do my eyes adjust to the dark and how long does it take?
- Keep It Cool: Uncovering Famous Fridge Brands for Each Home
- Florence's Uffizi Gallery moves treasures to safety after cyberattack
- Christopher Nolan's 'The Odyssey' trailer: See Anne Hathaway, Matt Damon and Tom Holland in 1st look at movie
- Nations for Rock Climbing
- Don’t let food poisoning crash your Thanksgiving dinner
- Europe's powerful Ariane 6 rocket launches Sentinel-1D Earth-observation satellite to orbit (video)
- Trump administration plan to reduce access to some student loans angers nurses, health care groups
- 2 of Earth's rarest lightning phenomena captured simultaneously in once-in-a-lifetime photo
- Figure out How to Really focus on Your Dental Inserts for Durable Outcomes
